Tarsons Products (TARSONS) Fundamentals 2026 — P/E 113.4x, Revenue Analysis | SniperIQ
Tarsons Products (TARSONS) is a India-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ₹1,629 Crore, trading at ₹306.25 on the NSE. This SniperIQ fundamentals page covers Tarsons Products's valuation (P/E 113.4x, P/B 2.6x), profitability (net margin 3.4%), revenue (₹423 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tarsons Products's market cap?
Tarsons Products (TARSONS) has a market capitalization of approximately ₹1,629 Crore, trading at ₹306.25 on the NSE. Market cap moves with the live share price.
What is Tarsons Products's P/E ratio?
Tarsons Products's trailing twelve-month P/E ratio is 113.4x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tarsons Products?
Tarsons Products runs a net profit margin of 3.4%, a gross margin of 35.4%, and an operating margin of 5.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tarsons Products generate?
Tarsons Products reported revenue of ₹423 Crore for fiscal year 2026, with net income of ₹14 Crore and earnings per share (EPS) of 2.69. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tarsons Products pay a dividend?
Tarsons Products does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Tarsons Products financially healthy?
Tarsons Products carries a debt-to-equity ratio of 0.62x and a current ratio of 1.01x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tarsons Products a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tarsons Products (TARSONS) the key facts are: market cap ₹1,629 Crore, P/E 113.4x, revenue ₹423 Crore, 52-week range 164.45-386.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tarsons Products's full fundamentals live
Get Tarsons Products's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.